Rivaroxaban-Related Traumatic Large Subcutaneous Hematoma in the Calf Requiring Surgical Repair in an Elderly Patient

Yuki Tsujimoto; Goshi Matsuki; Yuki Noboru; Yoichi Nishii; Shinsaku Imashuku

doi:10.1055/s-0040-1710359

TH Open, Inhaltsverzeichnis

CC BY 4.0 · TH Open 2020; 04(02): e104-e106
DOI: 10.1055/s-0040-1710359

Letter to the Editor

Georg Thieme Verlag KG Stuttgart · New York

Rivaroxaban-Related Traumatic Large Subcutaneous Hematoma in the Calf Requiring Surgical Repair in an Elderly Patient

Yuki Tsujimoto

¹Division of Plastic Surgery, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan

,

Goshi Matsuki

²Department of Surgery, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan

,

Yuki Noboru

¹Division of Plastic Surgery, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan

,

Yoichi Nishii

¹Division of Plastic Surgery, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan

,

Shinsaku Imashuku

³Department of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan

References
1 Vimalesvaran K, Dockrill SJ, Gorog DA. Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. Vasc Health Risk Manag 2018; 14: 13-21
2 Koba S, Yamaguchi T, Miki K, Makihara H, Imashuku S. Management of chronic disseminated intravascular coagulation associated with aortic aneurysm/dissection. Case Rep Hematol 2019; 2019: 6204652
3 Beynon C, Potzy A, Sakowitz OW, Unterberg AW. Rivaroxaban and intracranial haemorrhage after mild traumatic brain injury: a dangerous combination?. Clin Neurol Neurosurg 2015; 136: 73-78
4 Grandhi R, Newman WC, Zhang X. , et al. Administration of 4-factor prothrombin complex concentrate as an antidote for intracranial bleeding in patients taking direct factor Xa inhibitors. World Neurosurg 2015; 84 (06) 1956-1961
5 Majeed A, Ågren A, Holmström M. , et al. Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood 2017; 130 (15) 1706-1712
6 Hori M, Matsumoto M, Tanahashi N. , et al; J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation—the J-ROCKET AF study. Circ J 2012; 76 (09) 2104-2111
7 Tao J, Bukanova EN, Akhtar S. Safety of 4-factor prothrombin complex concentrate (4F-PCC) for emergent reversal of factor Xa inhibitors. J Intensive Care 2018; 6: 34
8 Connolly SJ, Crowther M, Eikelboom JW. , et al; ANNEXA-4 Investigators. Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380 (14) 1326-1335
9 Crowther M, Cuker A. How can we reverse bleeding in patients on direct oral anticoagulants?. Kardiol Pol 2019; 77 (01) 3-11
10 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
11 Levy JH, Moore KT, Neal MD. , et al. Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers. J Thromb Haemost 2018; 16 (01) 54-64